跳至主要内容
临床试验/NCT05957458
NCT05957458已完成不适用

Retrospective Study of Photobiomodulation Therapy on Myopia Control With Airdoc Red Light at Wavelength of 650nm

Beijing Airdoc Technology Co., Ltd.1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2021年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
300
试验地点
1
主要终点
Axial length shortening comparing to that value of baseline (mm)

研究概览

简要总结

Photobiomodulation therapy, that is, Low-level red-light technology provides a new and innovative myopia control approach. This strategy enables relatively high energies of light to be delivered at much shorter durations of exposure to induce the myopia control effect. The efficacy of the low-level red-light technology has been proven in a Chinese populationb for the recent 3 years with evidence based papers and amazing results. However, there's not yet evidence to demonstrate the relationship between the dose response effect of photobiomodulation therapy on myopia control at the different age lever.

详细描述

Previous trial has demonstrated that 3-minutes per session twice a day repeated low-level red-light treatment at the irridiance of 2.3mW(2.0~2.5mW) controlled 87.7% of refraction progression and 76.8% of axial length elongation when the time of compliance to the treatment was 75%. Retrospective analyze other irriadance of 1.2mW, 0.6mW and 0.37mW culturally diverse groups will confirm and translate this technology into a solution for myopia control globally.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

盲法说明

No mask for all. Open and retrospective study.

入排标准

年龄范围
4 Years 至 41 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Myopia or near Myopia with younger age
  • Without other intervention of myopia control, including atropine, Misight contact lens, special design lens to control myopia, orthokeratology and other red light devices.
  • Follow-up at least once
  • With baseline data of ocular parameters before the follow-up

排除标准

  • Photophobia
  • Allergy to red light
  • Severe ocular progressing diseases or systemic diseases
  • The data is unacceptable with reasonable explanations

结局指标

主要结局

Axial length shortening comparing to that value of baseline (mm)

时间窗: 6-month

Measured with optial coherent methods with the same device assistant with the same techinician

次要结局

  • Refractive changes at the follow-up from the baseline (D)(12-month)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验